Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy after cytoreductive surgery outcome.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e17100-e17100
Author(s):  
Makoto Yamamoto ◽  
Tetuya Tujikawa ◽  
Hidehiko Okazawa ◽  
Yasushi Kiyono ◽  
Yoshio Yoshida
Keyword(s):  
Ovarian Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Cytoreductive Surgery ◽  
Tumor Burden ◽  
Surgery Outcome ◽  
Metabolic Tumor Burden

scholarly journals Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum‐based adjuvant chemotherapy

2016 ◽  
Vol 107 (4) ◽  
pp. 478-485 ◽  
Author(s):  
Makoto Yamamoto ◽  
Tetsuya Tsujikawa ◽  
Yuko Fujita ◽  
Yoko Chino ◽  
Tetsuji Kurokawa ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Tumor Burden ◽  
Metabolic Tumor Burden

scholarly journals Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome

2019 ◽  
Vol 26 (9) ◽  
pp. 2943-2951 ◽  
Author(s):  
Marcia Hall ◽  
Konstantinos Savvatis ◽  
Katherine Nixon ◽  
Maria Kyrgiou ◽  
Kuhan Hariharan ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Cytoreductive Surgery ◽  
Tumor Burden ◽  
High Tumor Burden ◽  
Maximal Effort

A matched pair analysis of intra- and postoperative catumaxomab in patients with ovarian cancer from a multicenter, single-arm phase II trial versus a consecutive single-center collective of ovarian cancer patients without immunotherapy.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 5080-5080 ◽  
Author(s):  
Klaus Pietzner ◽  
Radoslav Chekerov ◽  
Alexander Reinthaller ◽  
Daniel Reimer ◽  
Toralf Reimer ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Cytoreductive Surgery ◽  
Matched Pair ◽  
Control Group ◽  
Matched Pair Analysis ◽  
Matching Criteria ◽  
Pair Analysis

5080 Background: Advanced ovarian cancer is still connected to high mortality rates due to intraperitoneal tumor cells that survive radical cytoreductive surgery as well as adjuvant chemotherapy. These persistent tumor cells need to be targeted in order to improve survival. Catumaxomab has demonstrated the ability to kill EpCAM-positive intraperitoneal tumor cells of ovarian cancer patients in studies aiming to controll malignant ascites in the recurrent setting. This analysis was conducted to investigate the efficacy of intraperitoneal catumaxomab at the timepoint of primary cytoreductive surgery and postoperative period, prior to standard adjuvant chemotherapy. Methods: Ovarian cancer patients undergoing radical surgery received one intraoperative (10 μg) followed by four subsequent intraperitoneal (i.p.) dosages (10, 20, 50 and 150 μg) of catumaxomab on days 7, 10, 13, and 16, respectively. Because of the single arm design of the study, the patients treated with catumaxomab were compared in a matched pair analysis to consecutive patients with primary ovarian cancer who received standard treatment without catumaxomab in a large center, in order to compare survival. The two main prognostic factors of stage and level of tumorreduction were chosen as matching criteria. Results: Of 58 patients screened, 41 were treated with catumaxomab and available for survival evaluation. Median age was 57 years in the catumaxomab group and 59 years in the matched-pair control group. The most comon histology was the serous subtype with 70.7 % in the catumaxomab and 80.5 % of the patients in the control group. The median for overall survival was reached for the historical consecutive matched-pair control collective, but is not yet reached for the catumaxomab group. However, 3-year survival data were available for both groups and showed survival of 85.4% (35) in the catumaxomab group and 63.4% (26) in the matched-pair control group (p-value: 0.041; HR 2.073) Conclusions: There seems to be a trend to beneficial 3-year survival in the catumaxomab group, suggesting that a phase III trial is warranted.

scholarly journals Predictive Value of Aurora-A/STK15 Expression for Late Stage Epithelial Ovarian Cancer Patients Treated by Adjuvant Chemotherapy

2007 ◽  
Vol 13 (14) ◽  
pp. 4083-4091 ◽  
Author(s):  
Silke Lassmann ◽  
Yi Shen ◽  
Uta Jütting ◽  
Philipp Wiehle ◽  
Axel Walch ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Adjuvant Chemotherapy ◽  
Epithelial Ovarian Cancer ◽  
Cancer Patients ◽  
Late Stage ◽  
Predictive Value ◽  
Aurora A

scholarly journals Factors predict postoperative morbidity in advanced stage ovarian cancer patients who underwent cytoreductive surgery: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Malika Kengsakul ◽  
Gatske M. Nieuwenhuyzen-de Boer ◽  
Suwasin Udomkarnjananun ◽  
Stephen J. Kerr ◽  
Christa D. Niehot ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ovarian Cancer ◽  
Cancer Patients ◽  
Cytoreductive Surgery ◽  
Postoperative Morbidity ◽  
Meta Analysis ◽  
Advanced Stage
Sign in / Sign up

Export Citation Format

Share Document